MedTrace Logo

Hepatitis B Vaccination in HIV-infected Persons

NCT00230061 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 800

Last updated 2010-06-02

No results posted yet for this study

Summary

In this study we compare the efficacy of two different HBV-vaccination schedules in HIV-infected persons concerning immune response and compliance. Short schedule: t=0,1,3 weeks and standard schedule: t=0,1,6 months.

Conditions

Interventions

BIOLOGICAL

HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml

Sponsors & Collaborators

Principal Investigators

  • Theodora EM de Vries-Sluijs, MD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2008-05-31
Completion
2010-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00230061 on ClinicalTrials.gov